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I. INTRODUCTION 
We are on the leading edge of a true revolution in medicine, one 
that promises to transform the traditional ‘one size fits all’ 
approach into a much more powerful strategy that considers each 
individual as unique and as having special characteristics that 
should guide an approach to staying healthy.  Although the 
scientific details to back up these broad claims are still evolving, 
the outline of a dramatic paradigm shift is coming into focus.1 
Francis S. Collins, Director of National Institutes of Health 
 
 * J.D., 2005, New York University of Law; M.A., 2009, Aarhus University. 
1.  FRANCIS S. COLLINS, THE LANGUAGE OF LIFE: DNA AND THE REVOLUTION IN 
PERSONALIZED MEDICINE xxiii–xxiv (2010).   
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The growth of personalized medicine, which aims to better 
customize and target treatments to patients through the use of 
information about an individual’s genes, proteins, and environment, is 
changing the healthcare industry and holds tremendous potential to 
improve patients’ lives.  The medical diagnostics field is a key attribute 
of personalized medicine, as simple tests measuring levels of proteins, 
genes, or mutations can be performed on patients to optimize specific 
therapies for that individual’s condition.  In many cases, this 
individualized treatment avoids costly, unnecessary, and potentially 
dangerous procedures. 
Within the medical diagnostics field, genetic diagnostic methods are 
rapidly changing the way diseases are diagnosed, prevented, and 
treated.  The ability to link genetic mutations to specific diseases can 
lead to improved diagnostics, higher quality health care and, in some 
instances, life-saving treatments.  Current estimates place the number of 
inheritable diseases stemming from mutated genes at four thousand.2  
Thus far, genetic information has been used to assist physicians in 
individualizing treatments for their patients in a variety of contexts.  
And, “most of the promise offered by the sequencing of the human 
genome still lies ahead.”3 
Although personalized medicine remains in its early stages, its 
potential to improve patients’ lives cannot be overstated.  However, 
translating this seemingly limitless scientific revolution into tangible 
benefits for patients and ensuring that these discoveries are accessible 
on reasonable and fair terms to patients promises to be a difficult 
challenge.  As our understanding of the linkages between genetic 
mutations and diseases has grown, so has a heated debate over whether 
patents on genes are deserving of patent protection.  Currently, genetic 
diagnostic methods can be broadly claimed in a patent.4  These 
diagnostic gene patents typically involve the process of comparing a 
particular portion of a patient’s genetic sequence to a wild-type or 
mutation sequence in order to diagnose a genetic predisposition or 
disease.  These patents oftentimes claim every single known and 
possible method for looking at the DNA sequence, including many of 
 
2.  Biotechnology Industry Organization, National Issues, Intellectual Property, 
available at http://web.archive.org/web/20101119211310/http://bio.org/ip/primer/genehelps.asp 
(last visited Sept. 7, 2011).   
3.  COLLINS, supra note 1, at 3.   
4.  Metabolite Labs. Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1361–66 (Fed. 
Cir. 2004).   
RUSSELL- FORMATTED (DO NOT DELETE) 11/15/2011  11:09 AM 
2012]   UNLOCKING THE GENOME 83 
 
the standard processes regularly employed in the field.  Over the past 
few decades, the U.S. Patent and Trademark Office (PTO) has granted 
thousands of patents on human genes, many of these directed towards 
diagnostic methods.  Presently, patents are held on diagnostic tests tied 
to a wide array of diseases including prostate cancer,5 HIV/AIDS,6 
breast cancer,7 ovarian cancer,8 and vitamin B deficiencies.9  Half of the 
genes known to be connected to cancer are already patented, and one 
company alone holds patents on approximately ten percent of the 
human genome.  Whether such advanced diagnostic methods should be 
afforded patent protection is of increasing significance as our 
understanding of the makeup of the human genome grows. 
The wisdom of patenting genetic diagnostic methods, particularly 
whether or not such patents promote or prevent medical and scientific 
advancements, is a hotly debated issue.  Supporters of such patents 
argue that they are deserving of patent protection because they 
accelerate scientific discoveries and improve medical care by 
incentivizing investment into research.  Critics of patents held on 
diagnostic methods argue that many of these patents actually fall within 
the judicial exceptions to patentable subject matter because they claim 
such patents are laws of nature, natural phenomena, or abstract ideas.  
They advance numerous policy arguments against them as well, namely 
that they are unnecessary to motivate innovation and 
commercialization, that they have a chilling effect on medical and 
scientific research, and that they result in a lower standard of medical 
care.  Because patents provide the ability to extract monopoly rent, in 
cases where those rents are beyond what is necessary to encourage 
innovation, overbroad patent protection comes with very real costs both 
to consumers and innovation. 
This paper examines whether genetic diagnostic patents constitute 
patentable subject matter under 35 U.S.C. § 101.  Part II examines the 
jurisprudence surrounding the boundaries of patentable subject matter.  
Part III presents a brief background on the science of genetics and the 
history of gene patents.  Part III also traces the litigation in Association 
for Molecular Pathology v. United States Patent and Trademark Office, 
and concludes by arguing that diagnostic genetic patents, as well as 
 
5.  U.S. Patent No. 5,840,501 (filed July 31, 1997).   
6.  U.S. Patent No. 5,838,352 (filed Dec. 16, 2003).   
7.  U.S. Patent No. 5,709,999 (filed June 7, 1995).   
8.  U.S. Patent No. 4,968,603 (filed Dec. 31, 1986).   
9.  U.S. Patent No. 4,940,658 (filed Nov. 20, 1986).   
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other advanced diagnostic method patents, constitute non-patentable 
subject matter under 35 U.S.C. § 101.  Part IV presents several policy 
arguments against granting patents on diagnostic methods. 
II. PATENTING PROCESSES 
The courts have struggled in determining the proper boundaries for 
patentable subject matter, particularly when applied to process patents.  
The Constitution grants Congress broad power to legislate to “promote 
the [p]rogress of [s]cience and useful [a]rts, by securing for limited 
[t]imes to [a]uthors and [i]nventors the exclusive [r]ight to their 
respective [w]ritings and [d]iscoveries.”10  Patents promote scientific 
progress by offering inventors a monopoly for a limited period of time 
in order to incentivize innovation.11  Patents can be obtained for several 
types of inventions, including a process, machine, manufacture, or 
composition of matter.12  Patent-holders have the absolute right to 
exclude others from making, using, or selling their invention for twenty 
years after the application for the patent is filed.13  Properly employed, 
patents incentivize innovation, promote the disclosure of information, 
and offer protection for commercialization.  However, patent law 
necessitates a careful balancing between promoting innovation while 
not stifling scientific research and development.  In some cases, “too 
much patent protection can impede rather than ‘promote the Progress 
of Science and useful Arts,’ the constitutional objective of patent and 
copyright protection.”14 
Thus, in order to receive the Patent Act’s protection, a claimed 
invention must be novel,15 nonobvious,16 and fully and particularly 
described.17  However, before a court may even turn to these 
requirements, it must first determine the threshold issue of whether the 
invention for which patent protection is sought is patentable subject 
matter under 35 U.S.C. § 101.18  While patent protection may be applied 
 
10.  U.S. CONST., art.1, § 8, cl. 8.  
11.  Diamond v. Chakrabarty, 447 U.S. 303, 307 (1980). 
12.  35 U.S.C. § 101 (2006). 
13.  35 U.S.C. § 154 (2006). 
14.  Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S. 124, 126–27 (2006) 
(Breyer, J., dissenting) (quoting U.S. CONST., art. 1, § 8, cl. 8). 
15.  35 U.S.C. § 102 (2006).  
16.  35 U.S.C. § 103 (2006). 
17.  35 U.S.C. § 112 (2006). 
18.  The inquiry into an invention's patent eligibility is a fundamental one, and as such, 
“[t]he obligation to determine what type of discovery is sought to be patented must precede 
the determination of whether that discovery is, in fact, new or obvious.”  Parker v. Flook, 437 
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to “anything under the sun that is made by man,”19 this expansive 
reading is not without its limits.  The Supreme Court has recognized 
three categories of subject matter that fall outside of § 101 and are not 
patentable: the laws of nature, physical phenomena, and abstract ideas.20  
In explaining the reasoning behind these exceptions, the Supreme Court 
has noted as follows: 
[A] new mineral discovered in the earth or a new plant found in 
the wild is not patentable subject matter.  Likewise, Einstein 
could not patent his celebrated law that E=mc2; nor could 
Newton have patented the law of gravity.  Such discoveries are 
“manifestations of . . . nature, free to all men and reserved 
exclusively to none.”21 
The rule that the discovery of a law of nature is unpatentable rests 
on the understanding that they are not the type of discovery that the 
patent laws were enacted to protect.22  These fundamental principles 
“even when for the first time discovered, have existed throughout time, 
define the relationship of man to his environment, and, as a 
consequence, ought not to be the subject of exclusive rights to any one 
person.”23  They “are part of the storehouse of knowledge of all men . . . 
free to all men and reserved exclusively to none.”24  As Justice Breyer 
eloquently observed the reasoning behind these exceptions: 
The justification for the principle does not lie in any claim that 
‘laws of nature’ are obvious, or that their discovery is easy, or 
that they are not useful.  To the contrary, research into such 
 
U.S. 584, 593 (1978). 
19.  Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (quoting S. Rep. No. 1979, at 6 
(1952), reprinted in 1952 U.S.C.C.A.N. 2394, 2398, 2409–10).  Although often cited, this 
phrase is somewhat misleading as the full quote, which originally appeared in the legislative 
history of the Patent Act of 1952, reads “[a] person may have ‘invented’ a machine or a 
manufacture, which may include anything under the sun made by man, but it is not 
necessarily patentable under section 101 unless the conditions of [this] title are fulfilled.”  S. 
Rep. No. 1979, at 6 (1952), reprinted in 1952 U.S.C.C.A.N. 2394, 2398, 2409–10.  In Bilski v. 
Kappos, Justice Stevens reiterated the point that just because a person may have “‘invented’ 
. . . anything under the sun,” that thing is not necessarily patentable under § 101.  130 S. Ct. 
3218, 3249 (2010) (Stevens, J., concurring). 
20.  Chakrabarty, 447 U.S. at 309.   
21.  Id. (quoting Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948)).   
22.  Parker v. Flook, 437 U.S. 584, 593 (1978). 
23.  In re Meyer, 688 F.2d 789, 795 (C.C.P.A. 1982) (citing Le Roy v. Tatham, 55 U.S. 
156, 175 (1852)).   
24.  Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948).   
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matters may be costly and time consuming; monetary incentives 
may matter; and the fruits of those incentives and that research 
may prove of great benefit to the human race.  Rather, the 
reason for this exclusion is that sometimes too much patent 
protection can impede rather than ‘promote the Progress of 
Science and useful Arts,’ the constitutional objective of patent 
and copyright protection.25 
Unfortunately, the fundamental principles exception can be a 
difficult standard to apply particularly when assessing the patentability 
of process claims.  A process claim involves any series of steps “to 
produce a given result.”26  The prohibition against patenting 
fundamental principles does not necessitate that all processes which 
incorporate fundamental principles necessarily fall outside the scope of 
patent protection.27  The application of a law of nature in a new and 
useful way may very well be deserving of patent protection.  To find 
otherwise would, “if carried to its extreme, make all inventions 
unpatentable because all inventions can be reduced to underlying 
principles of nature which, once known, make their implementation 
obvious.”28  Rather, whether a method patent constitutes patentable 
subject matter turns upon whether the patent application attempts to 
patent a fundamental principle, i.e. a natural correlation, or simply 
incorporates it into a new and useful process.  Unfortunately, 
determining whether a patent application seeks to incorporate a law of 
nature into a new and useful series of steps or is an attempt to 
circumvent the fundamental principles exception through crafty 
draftsmanship can be a challenging task. 
Over the past few decades, the Supreme Court has offered minimal 
guidance as to how to best determine whether a process patent is drawn 
to statutory subject matter.  Given the Supreme Court’s reticence in this 
area, the Federal Circuit has been left to wrestle with this issue over the 
past several decades.  In 1998, the Federal Circuit addressed this issue in 
a case involving business patents—State Street Bank & Trust Co. v. 
Signature Financial Group, Inc.—which held that a “process” claim 
would be patentable subject matter so long as it provided “a useful, 
 
25.  Lab. Corp. of Am. Holdings, 548 U.S. at 126–27 (2006) (Breyer, J., dissenting) 
(quoting U.S. CONST., art. 1, § 8, cl. 8).   
26.  Cochrane v. Deener, 94 U.S. 780, 788 (1877). 
27.  In re Bilski, 545 F.3d 943, 958 (Fed. Cir. 2008) (citations omitted). 
28.  Diamond v. Diehr, 450 U.S. 175, 189 n.12 (1981). 
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concrete, and tangible result.”29  However, this test was later thrown into 
doubt in dicta penned by Justice Breyer in Metabolite Labs. Inc. v. Lab. 
Corp. of Am. Holdings, when he pointedly critiqued the State Street 
decision, by noting that the Supreme Court “never made such a 
statement and, if taken literally, the statement would cover instances 
where this Court has held the contrary.”30  The Federal Circuit later 
revisited the issue in In re Bilski, and perhaps in an attempt to correct 
the overly broad standard of State Street, articulated a bright-line rule 
for determining whether a method patent is patent-eligible.  In Bilski, 
the Federal Circuit examined whether a business method for using 
commodity exchange transactions to hedge risks was patentable subject 
matter.31  In its decision, the Federal Circuit struggled to outline more 
definitive guidelines as to what constitutes a patentable process.  
Acknowledging the inherent tension in applying the fundamental 
principles exception to process patents, the Federal Circuit stated that 
any inquiry as to whether a process is patent eligible should seek to 
“determine whether [the] process claim is tailored narrowly enough to 
encompass only a particular application of a fundamental principle 
rather than to pre-empt the principle itself.”32 
In Bilski, the Federal Circuit ultimately adopted the “machine-or-
transformation” test as the exclusive test for making this pre-emption 
decision.33  Under this test, a claimed process is patent eligible if “(1) it is 
tied to a particular machine or apparatus, or (2) it transforms a 
particular article into a different state or thing.”34  Furthermore, the 
transformation “must be central to the purpose of the claimed process”35 
and must not be “insignificant extra-solution activity” or merely a “data-
 
29.  See State Street Bank & Trust Co. v. Signature Fin. Group, 149 F.3d 1368, 1375 
(Fed. Cir. 1998) (quoting In re Alappat, 33 F.3d 1526, 1544 (Fed. Cir. 1994)). 
30.  Lab. Corp. of Am. Holdings, 548 U.S. at 136.  
31.  In re Bilski, 545 F.3d at 949–51.  Claim 1 of the petitioner’s application stated as 
follows:  
A method for managing the consumption of risk costs of a commodity [,] comprising 
the steps of: (a) initiating a series of transactions between [a] commodity provider 
and consumers of said commodity . . . ; (b) identifying market participants for said 
commodity . . . ; (c) initiating a series of transactions between said commodity 
provider and said market participants . . . such that said series of market participant 
transactions balances the risk position of said series of consumer transactions.   
Id. at 949. 
32.  Id. at 954.   
33.  Id. at 966.   
34.  Id. at 954. 
35.  Id. at 962.  
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gathering step.”36  Phrased differently, a patentee “cannot rely on the 
data-gathering steps to prove that the claimed process is transformative 
and thus drawn to patentable subject matter.”37 
Last year, the Supreme Court took the case up on appeal, and for 
the first time since its decision in Diamond v. Diehr in 1981, the 
Supreme Court addressed the boundaries of patentable subject matter 
in Bilski v. Kappos.  In an eagerly awaited decision, the Court upheld 
the Federal Circuit’s decision to strike down the business method 
patents on the basis that they were attempts to patent abstract ideas 
while simultaneously overturning the “machine-or-transformation” test 
as the exclusive means for determining the patent eligibility of 
processes.38  Rejecting the Federal Circuit’s exclusive reliance on the 
“machine-or-transformation” test, the Supreme Court acknowledged 
that “new technologies may call for new inquiries.”39  Thus, the 
machine-or-transformation test, which had been relied upon in 
numerous cases during the interim, including several cases involving 
patents on diagnostic methods, is no longer the sole test for determining 
whether an invention is patentable subject matter under 35 U.S.C. § 
101.40 
The Court did not, however, formulate a new test for determining 
what constitutes patentable subject matter and chose instead to reiterate 
the long-standing rule that bars patents for laws of natures, physical 
phenomena, or abstract ideas.  Although some hoped Bilski would 
provide concrete guidance as to when process claims constitute 
patentable subject matter, the Court ultimately opted for a narrow 
ruling.  Offering minimal guidance as to what other considerations or 
tests might apply in determining what constitutes a patentable 
“process,” the Court instead referred back to the language of § 100(b)41 
and its earlier decisions in Gottschalk v. Benson, Parker v. Flook, and 
 
36.  Id. at 963 (providing that “[f]urther, the inherent step of gathering data can also 
fairly be characterized as insignificant extra-solution activity.”). 
37.  Prometheus Labs., Inc. v. Mayo Collaborative Servs., 581 F.3d 1336, 1343 (Fed. 
Cir. 2009), vacated sub nom, Mayo Collaborative Servs. v. Prometheus Labs., Inc., 130 S. Ct. 
3543 (2010) (“stating that mere data-gathering will not ‘at least in most cases, . . . constitute a 
transformation of any article.’”).   
38.  Bilski v. Kappos, 130 S. Ct. 3218, 3227, 3229 (2010). 
39.  Id. at 3228. 
40.  See generally id.  
41.  35 U.S.C. § 100(b) (2006) (Section 100(b) defines a process, in a somewhat circular 
fashion, as a “process, art or method, and includes a new use of a known process, machine, 
manufacture, composition of matter or material.”). 
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Diamond v. Diehr.42  Because, as Justice Stevens pointed out in his 
concurrence in Bilski v. Kappos, the Court “never provides a satisfying 
account of what constitutes an unpatentable abstract idea,”43 
practitioners and academics are left struggling to define the implications 
the decision holds.  In order to unpack the potential implications Bilski 
v. Kappos may hold for process patents and specifically diagnostic 
process patents, an overview of the three cases Bilski cites is instructive.  
All three struggle to distinguish between instances when a patent 
application seeks to patent a fundamental principle and when it simply 
seeks to incorporate a fundamental principle into a series of steps 
deserving of patent protection.  Indeed, they all struggle with the 
challenge that “[w]hen a claim contains a natural phenomenon, the 
court must determine whether the claim is merely seeking to patent the 
phenomenon itself by describing it in abstract process terms.”44 
Gottschalk v. Benson involved a patent application claiming an 
algorithm that converted binary-coded decimal numerals into pure 
binary code.45  In holding that the application embodied an unpatentable 
abstract idea, the Court reiterated the fact that patent-eligible processes 
must include “the application of the law of nature to a new and useful 
end.”46  The Court emphasized the fact that the patent application would 
“wholly pre-empt” the fundamental principle, and in all practicality, 
would be a patent on the fundamental principle itself.47 
The theory of preemption is of critical importance in determining 
the patentability of a process incorporating a fundamental principle and 
is returned to in the Court’s later decisions.  In Parker v. Flook, the 
Court further refined the theory of preemption by holding that a 
process need not preempt all uses of a fundamental principle in order to 
fall within the fundamental principles exception.  There, the patent at 
issue was for a method to update an “alarm limit.”  The method 
consisted of three steps: (1) a measurement of a given variable followed 
by (2) a mathematical calculation to arrive at a new alarm limit value 
ending with (3) adjustment of the limit to correspond to that new value.  
The Court further refined the theory of preemption in rejecting the 
 
42.  Bilski, 130 S. Ct. at 3222.  
43.  Id. at 3236 (Stevens, J., concurring). 
44.  Classen Immunotherapies, Inc. v. Biogen Idec, 2006 WL 6161856, at *4 (D. Md.) 
(citing Diamond v. Diehr, 450 U.S. 175, 192 (1981)). 
45.  Gottschalk v. Benson, 409 U.S. 63, 64–71 (1972).  
46.  Id. at 67 (quoting Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 
(1948)).   
47.  Id. at 72.   
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argument that simply because “all possible uses of the mathematical 
formula were not pre-empted, the claim should be eligible for patent 
protection,”48 noting that, “[a] mathematical formula does not suddenly 
become patentable subject matter simply by having the applicant 
acquiesce to limiting the reach of the patent for the formula to a 
particular technological use.  A mathematical formula in the abstract is 
non-statutory subject matter regardless of whether the patent is 
intended to cover all uses of the formula or only limited uses.”49  
Furthermore, the Court held that the fact that the mathematical 
algorithm was followed by the “‘post–solution’ activity” of an 
adjustment of the limit was not enough to transform an unpatentable 
principle into a patentable method.50  Stripped of the post solution 
activity, the method consisted of little more than plugging a variable 
into a formula.  The Court thus further refined the theory of preemption 
by rejecting “[t]he notion that post-solution activity, no matter how 
conventional or obvious in itself, can transform an unpatentable 
principle into a patentable process.”51  Flook stands for the principle that 
the prohibition against patenting abstract ideas “cannot be 
circumvented by attempting to limit the use of the formula to a 
particular technological environment” or adding “insignificant post-
solution activity.”52  The Court concluded that the process at issue there 
was “unpatentable under § 101, not because it contain[ed] a 
mathematical algorithm as one component, but because once that 
algorithm [wa]s assumed to be within the prior art, the application, 
considered as a whole, contain[ed] no patentable invention.”53  If the 
claim does not disclose another inventive concept, apart from the 
fundamental principle, it is unpatentable under § 101.54 
Of the three cases, Diamond v. Diehr was the only process patent 
the Court found eligible.  That case involved a previously unknown 
method for molding raw synthetic rubber into cured precision products 
using a mathematical formula to complete some of its several steps with 
the use of a computer.55  The Court held that a process claim involving a 
physical transformation of matter is patentable subject matter but 
 
48.  Diehr, 450 U.S. at 192 n.14 (1981). 
49.  Id.  
50.  Parker v. Flook, 437 U.S. 584, 590 (1978).  
51.  Id.  
52.  Diehr, 450 U.S. at 191–92. 
53.  Flook, 437 U.S. at 594.  
54.  Id. at 591–95. 
55.  Diehr, 450 U.S. at 177.   
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indicated that a process claim not involving a particular machine may 
still be patentable.56  Diehr affirmed that “an application of a law of 
nature or mathematical formula to a known structure or process may 
well be deserving of patent protection.”57  However, when a claim 
recites a fundamental principle, “an inquiry must be made into whether 
the claim is seeking patent protection for that formula in the abstract.”58  
Thus, while the claimed process must be considered as a whole, the 
inventive concept cannot derive solely from the fundamental principle. 
In summation, Bilski reaffirmed that preemption is the controlling 
standard for § 101 under the Court’s Benson, Flook, and Diehr 
precedents and that while the machine-or-transformation test may 
inform the analysis, that test is not outcome determinative.59  A careful 
reading of Bilski v. Kappos and these three decisions affirms that a 
patent cannot preempt, that is to say, foreclose all “practical 
application” of a fundamental principle.60  Thus the key consideration is 
whether the patent threatens to (a) wholly preempt the fundamental 
principle or (b) be the only practical and useful application of the 
principle.  This approach analyzes the extent to which a patent operates 
as a roadblock to other useful applications of the fundamental principle.  
Furthermore, limiting a fundamental principle to a particular industry or 
technological environment is not sufficient to make said claim patent 
eligible.  Simply because a correlation is a narrowly drawn one does not 
make it any less of a fundamental principle.  Placing insignificant 
limitations on a fundamental principle will not transform it into a 
patentable process, and neither will post-solution activity transform an 
unpatentable principle into a patentable process—this is especially true 
where the application considered as a whole contains no patentable 
invention.  Rather, there must be a significant application of the 
principle to what is, when reading the claim as a whole, a new and useful 
process.  Although the claimed process must be considered as a whole, 
the inventiveness and novelty of the process should not derive solely 
from the fundamental principle.  Finally, although the Supreme Court 
rejected the “machine-or-transformation” test as a categorical rule, it 
remains “an important and useful clue” and helpful “investigative tool” 
 
56.  Id. at 184. 
57.  Id. at 187.   
58.  Id. at 191.  
59.  Prometheus Labs., Inc. v. Mayo Collaborative Servs., 628 F.3d 1347, 1354 (Fed. 
Cir. 2010). 
60.  See Diehr, 450 U.S. at 185–86 (citing Gottschalk v. Benson, 409 U.S. 63, 67 (1972)); 
see generally Bilski v. Kappos, 130 S. Ct. 3218 (2010). 
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in determining whether some claimed processes are patent eligible 
under § 101.61  In short, the machine-or-transformation remains a 
helpful, but at times inaccurate, proxy for assessing the more important 
challenge of “securing patents for valuable inventions without 
transgressing the public domain.”62 
III. PATENTS ON GENETIC DIAGNOSTIC METHODS 
Bilski v. Kappos may hold potential implications for the patenting of 
genetic diagnostic methods and other advanced diagnostic methods.  
Genetic diagnostic patents claim the process of comparing a wild-type 
DNA sequence against an individual’s DNA, in order to diagnose either 
the existence of or a predisposition to a particular disease.  These 
patents often claim all methods of comparing genetic sequences in a 
human subject to the genetic sequence in a control group63 and do not 
link the diagnoses to any particular equipment or machine.64  Genetic 
diagnostic patents currently exist for genes linked to breast cancer,65 
ovarian cancer,66 and Canavan Disease,67 to name just a few.  Whether 
such advanced diagnostic methods should be afforded patent protection 
is of increasing significance due to the advent of personalized medicine. 
Advanced diagnostic patents, particularly diagnostic genetic patents, 
highlight the inherent difficulties of assessing whether a claimed method 
seeks to patent a fundamental principle or simply incorporate it into a 
series of steps.  The Court explicitly acknowledged the challenging 
issues raised by diagnostic methods in Bilski when rejecting the 
machine-or-transformation test, by noting that “there are reasons to 
doubt whether the test should be the sole criterion for determining the 
patentability of inventions in the Information Age.  As numerous 
amicus briefs argue, the machine-or-transformation test would create 
uncertainty as to the patentability of . . . advanced diagnostic medicine 
techniques.”68  In short, the decision suggests that the Court believes the 
machine-or-transformation test was not up to the task of establishing 
the patentability of advanced diagnostic methods.  Unfortunately, the 
Court provided little further guidance as to what other tests or 
 
61.  Bilski, 130 S. Ct. at 3226–27. 
62.  Id. at 3227.   
63.  U.S. Patent No. 5,753,441 claim 1 (filed Jan. 5, 1996).   
64.  Id.   
65.  U.S. Patent No. 5,709,999 (filed June 7, 1995). 
66.  U.S. Patent No. 4,968,603 (filed Dec. 31, 1986). 
67.  U.S. Patent No. 5,679,635 (issued Oct. 21, 1997).   
68.  Bilski v. Kappos, 130 S. Ct. 3218, 3227 (2010). 
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considerations may apply for these discoveries, choosing instead to 
adopt a wait-and-see approach. 
The Supreme Court has been similarly reluctant to address the issue 
of diagnostic patents in the past.  In 2006, the Supreme Court granted 
certiorari in Metabolite Laboratories Inc. v. Laboratory Corporation of 
America Holdings to decide whether a method-of-diagnosis claim 
constituted patentable subject matter;69 however, the Court later 
dismissed certiorari as improvidently granted because the issue had not 
been argued in the lower courts.70  At that time, the Court opted to not 
rule on whether medical diagnostics were patentable and chose instead 
to allow the issue to percolate through the lower courts.  And so, over 
the past few years, several cases involving diagnostic methods have been 
raised to the Federal Circuit.  The Court’s ruling in Bilski v. Kappos 
may hold important implications for the patenting of genetic diagnostic 
methods as well as for other advanced medical diagnostic methods.  
Signaling its interest in the patentability of advanced diagnostic 
methods, the Supreme Court vacated and remanded two Federal Circuit 
opinions involving diagnostic patents the day after its ruling in Bilski v. 
Kappos, Prometheus Laboratories, Inc. v. Mayo Collaborative Services,71 
and Classen Immunotherapies, Inc. v. Biogen IDEC.72  Both cases 
involved patents on medical diagnostic processes and relied on the 
“machine-or-transformation” test in assessing the validity of the 
diagnostic patents—this test has now been thrown into question.73  In 
December 2010, the Federal Circuit reconsidered Prometheus and 
reached the same result it had originally, upholding the patents as valid 
under Section 101.74  Of particular interest to this issue is the case 
Association of Molecular Pathologists v. USPTO, which was recently 
ruled on by the Federal Circuit and was originally decided using the 
 
 69.    Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S. 124, 125 (2006). 
70.  Id.  
71.  Prometheus Labs., Inc. v. Mayo Collaborative Servs., 581 F.3d 1336, 1343 (Fed. 
Cir. 2009), vacated sub nom, Mayo Collaborative Servs. v. Prometheus Labs., Inc., 130 S. Ct. 
3543 (2010).   
72.  Classen Immunotherapies, Inc. v. Biogen IDEC, 304 F. App’x 866 (Fed. Cir. 2008) 
(holding that patents on the correlation between vaccination schedules and the risk of 
developing chronic immune mediated disorders were attempt to patent an unpatentable 
natural phenomenon). 
73.  The simultaneous remand of these two cases is interesting because in Prometheus 
the Federal Circuit held that the medical diagnostic claims at issue were valid while the 
Classen court upheld the district court’s holding of invalidity.   
74.  Prometheus Labs. v. Mayo Collaborative Servs., 628 F.3d 1347 (Fed. Cir. 2010), 
cert. granted, 131 S. Ct. 3027. 
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machine-or-transformation test.  In the district court case, the court 
invalidated fifteen claims drawn from seven patents tied to the breast 
cancer genes by finding that the diagnostic gene patents held on the 
breast cancer genes did not encompass patentable subject matter under 
35 U.S.C. § 101.75  This decision marked the first time a court had ruled 
on whether genetic diagnostic methods constitute patentable subject 
matter.76  While overturning much of the district court’s decision, the 
Federal Circuit Court of Appeals did uphold the lower court’s decision 
that several of the diagnostic gene patents were invalid.  The case may 
eventually reach the Supreme Court and their decision could reshape 
both the biotechnology industry and the law of intellectual property. 
A. Science of Genes 
Before turning to the legal issues surrounding genetic diagnostic 
patents, a brief summary of relevant basic principles of molecular 
biology and genetics is helpful.  DNA is a chemical molecule composed 
of repeating chemical units known as nucleotides or bases.77  DNA is 
composed of four nucleotides78 and typically exists as a double helix 
consisting of two intertwined strands of DNA that are chemically bound 
to each other through base pairing.79  Genes are the basic units of 
heredity and are responsible for the inheritance of discrete traits.80  Each 
gene is typically thousands of nucleotides long and contains the 
information used by the body to produce proteins.81  Genes contain both 
exons and introns: exons are the coding sequences necessary for the 
creation of proteins, and introns contain regulatory sequences that 
affect the body’s rate of production of the protein encoded by a gene.82  
The human genome, which is comprised of approximately 25,000 genes, 
is contained within almost every cell in the human body and defines 
 
75.  See Ass’n of Molecular Pathology v. U.S. Pat. & Trademark Office, 702 F. Supp. 
2d 181, 185 (S.D.N.Y. 2010), aff’d in part, No. 2010–1406, 2011 WL 3211513 (Fed. Cir. July 29, 
2011).   
76.  Cf. Intervet Inc. v. Merial Ltd., 617 F.3d 1282, 1293 (Fed. Cir. 2010) (Dyk, J., 
concurring) (observing that “thus far the question has evaded judicial review”).   
77.  See Ass’n of Molecular Pathology, 702 F. Supp. 2d at 193–94.  
78.  Id.  
79.  Id. at 194.  The four nucleotides that comprise DNA are adenine, thymine, 
cytosine and guanine.  Adenine always binds to thymine, and cytosine will always bind to 
guanine.   
80.  Id.  
81.  Id.  
82.  Id.  
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physical traits as well as influences the development of certain diseases.83 
DNA as it is found in the human body is sometimes referred to as 
“native DNA.”84  Native DNA can be extracted from its natural cellular 
environment through established laboratory techniques, and a particular 
segment of that DNA, such as a gene, can then be excised from the 
extracted material.  Such a segment of DNA nucleotides existing 
distinctly from the cellular components normally associated with native 
DNA is referred to as “isolated DNA.”85  The term isolated DNA can 
refer both to DNA originating from a cell and DNA which has been 
synthesized through chemical or biological means.86 
Scientists use the term “wild-type” to refer to the “normal” human 
gene sequence, i.e., the sequence of a gene without any variations.87  
Variations or “mutations” in the human genome can occur at different 
magnitudes.  Small scale mutations can manifest as slight sequence 
differences between the same genes in different individuals88 while large 
scale variations can include the addition or deletion of substantial 
chromosomal regions.89  While many mutations may have little to no 
effect on the body’s processes, others can interfere with the body’s 
processes and may correlate with an increased risk, or in some cases, 
near certainty, of developing a particular disease.90  There are also 
mutations, or variants, of uncertain significance (VUS), whose affect on 
the body is unknown. 
DNA sequencing involves determining the order of nucleotides 
within a DNA molecule.91  Once a gene has been sequenced, the 
information can be used in diagnostic testing to determine whether an 
individual’s gene contains mutations that have been associated with a 
particular disease or condition.92  Once the location of a gene is found, it 
is relatively simple to directly analyze the sequence of the DNA and 
identify the nucleotides comprising the gene.93  However, locating genes 
tied to various conditions is a much more difficult process.  In order to 
 
83.  Id.  
84.  Id. at 195. 
85.  Id. at 196. 
86.  Id. at 217. 
87.  Id. at 195. 
88.  Id.  
89.  Id.  
90.  Id.  
91.  Id. at 199. 
92.  Id.  
93.  Id. at 201. 
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locate genes tied to various conditions, scientists often use linkage 
analysis.  Linkage analysis uses correlations between the occurrence of 
cancer and the inheritance of certain DNA markers among family 
members to map the physical location of a particular gene.94  Successful 
linkage analysis requires large and genetically informative families, or 
kindreds, and detailed family information and can be a burdensome and 
time-consuming process. 
B. The History of Gene Patents 
The explosion of patents within the biotechnology industry, 
including genetic patents, can trace itself back to the convergence of two 
significant events in 1980.  That year, Congress passed the Bayh-Dole 
Act and the Supreme Court decided Diamond v. Chakrabarty.95  The 
Bayh-Dole Act allowed universities, research institutions, and other 
non-profit organizations to seek patent protection for inventions made 
with government funding and to retain the royalties on those patents for 
the first time.96  The ability to retain and license the patents from 
academic research led to significant monetary gains for many 
universities.  That same year, the Supreme Court decided Diamond v. 
Chakrabarty, a case involving a patent application for a genetically 
engineered bacterium capable of “digesting” multiple components of 
crude oil.97  The original patent application for the bacterium had been 
denied based on the argument that living organisms constitute 
unpatentable subject matter.  On appeal, the Supreme Court held for 
the first time that a living organism could constitute patentable subject 
matter under § 101.  In its oft-quoted opinion, the Court stated that 
patent protection “includes[s] anything under the sun that is made by 
man.”98 
Chakrabarty opened the door to gene patenting by holding that 
 
94.  Id. 
95.  Diamond v. Chakrabarty, 447 U.S. 303 (1980).   
96.  Bayh-Dole Act, 35 U.S.C. § 202 (2006).   
97.  Chakrabarty, 447 U.S. at 305. 
98.  Id. at 309 (quoting S. Rep. No. 1979, at 6 (1952), reprinted in 1952 U.S.C.C.A.N. 
2394, 2398, 2409–10).  Although often cited, this phrase is somewhat misleading as it first 
originally appeared in the legislative history of the Patent Act of 1952.  The full quote states 
“A person may have ‘invented’ a machine or a manufacture, which may include anything 
under the sun made by man, but it is not necessarily patentable under § 101 unless the 
conditions of the title are fulfilled.”  S. Rep. No. 1979, at 6 (1952), reprinted in 1952 
U.S.C.C.A.N. 2394, 2398, 2409–10.  In Bilski v. Kappos, Justice Stevens reiterated the point 
that just because a person may have ‘invented’ . . .  anything under the sun,” that thing is not 
necessarily patentable under § 101.  130 S. Ct. 3218, 3249 (Stevens, J., concurring). 
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biological materials were patentable subject matter under 35 U.S.C. § 
101.  Relatively soon after the decision in Chakrabarty, the first United 
States patents relating to “isolated DNA” were issued.99  Four years 
later, in 1991, the Federal Circuit held that “isolated and purified” DNA 
sequences constitute patentable subject matter.100  Since the Federal 
Circuit’s decision to permit the patenting of genes in 1991, the number 
of patent applications for genes has exploded.  A 2005 study published 
in Science found that approximately 20 percent of human genes are 
currently patented.101  According to another study, 4,382 of the 23,688 
genes listed in the database of the National Center for Biotechnology 
Information (“NCBI”) are explicitly claimed as intellectual property.102 
In 2001, the United States Patent and Trademark Office (PTO) 
published revised examination guidelines for the “utility” requirement 
of § 101.103  The guidelines attracted a large number of public comments 
regarding the patent eligibility of human genes given the astounding 
increase in these types of patent applications.  The agency’s response 
constitutes the only written expression of its views on the issue of 
genetic patents.  The PTO indicated that genetic sequences that have 
been “isolated and purified” do constitute patent-eligible matter.104  
They stated that, as long as the specification of a patent discloses a 
particular use for a gene, the “inventor’s discovery of a gene can be the 
basis for a patent on the genetic composition isolated from its natural 
state and processed through purifying steps that separate the gene from 
other molecules naturally associated with it.”105  Their rationale was that 
a DNA molecule that has been “isolated” is not a product of nature, and 
 
99.  See U.S. Patent No. 4,680,264 claim 27 (filed July 1, 1983) (claiming a recombinant 
vector rather than genomic DNA). 
100.  See Amgen Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1206 (Fed. Cir. 1991) 
(holding that a “gene is a chemical compound” and affirming patentability of claims directed 
to a “purified and isolated DNA sequence.”). 
101.  Kyle Jenson & Fiona Murray, Intellectual Property Landscape of the Human 
Genome, 310 SCI. 239, 239 (2005). 
102.  Ass’n of Molecular Pathology v. U.S. Pat. & Trademark Office, 702 F. Supp. 2d 
181, 185 (S.D.N.Y. 2010). 
103.  USPTO Utility Examination Guidelines, 66 Fed. Reg. 1092, 1093 (Jan. 5, 2001), 
available at http://ww.uspto.gov/web/offices/com/sol/notices/utilexmguide.pdf. 
104.  Id. (“An inventor’s discovery of a gene can be the basis for a patent on the 
genetic composition isolated from its natural state and processed through purifying steps that 
separate the gene from other molecules naturally associated with it.”); see also Secretary’s 
Advisory Committee on Genetics, Health and Society, 110 Draft Report on Gene Patents 
and Licensing Practices and Their Impact on Patient Access to Genetic Tests 24 (Mar. 9, 
2009).   
105.  USPTO Utility Examination Guidelines, 66 Fed. Reg. 1092, 1093 (Jan. 5, 2001), 
available at http://ww.uspto.gov/web/offices/com/sol/notices/utilexmguide.pdf.  
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therefore unpatentable, because (1) “that DNA molecule does not 
occur in that isolated form in nature;” and (2) the purified state of 
synthetic DNA preparations “is different from the naturally occurring 
compound.”106 
The PTO stopped short of allowing patents on gene sequences as 
they exist in a person’s body.  Thus, today the term “gene patent” is 
more commonly used to refer to a wide variety of patents relating to 
genes but not on patents directed towards genes as they exist in the 
human body.  There are several different categories of patents tied to 
genetics, including composition-of-matter patents on isolated nucleic 
acid molecules and diagnostic genetic patents.  Composition-of-matter 
gene patents claim the “isolated and purified” DNA or cDNA 
sequences as explained above.  These isolated DNA sequences are often 
used as probes, which molecular biologists use to target and bind to 
particular portions of a patient’s DNA thereby allowing it to be 
detectable using laboratory machinery.107  Diagnostic genetic patents 
involve patent claims to processes for the detection of particular nucleic 
acid sequences or mutations using probes, primers, or some other 
method.  In short, these patents claim the process of comparing a wild-
type DNA sequence against an individual’s DNA, in order to diagnose 
either the existence of or a predisposition to a particular disease. 
C. Association for Molecular Pathology v. USPTO 
The debate over diagnostic patents recently came to a head in 
litigation surrounding two genes linked to breast and ovarian cancer.108  
In March of 2010, the Southern District of New York addressed the 
validity of genetic diagnostic patents in Association for Molecular 
Pathology v. United States Patent and Trademark Office.109  The highly-
watched case involved patents held on the BRCA1 and BRCA2 genes 
or, as they are more commonly known, the breast cancer genes.  Certain 
mutations in these two genes are associated with a highly increased risk 
of breast and ovarian cancer, and genetic testing for these mutations can 
 
106.  Id.  
107.  Defendant’s Memorandum of Law In Support of their Motion for Summary 
Judgment and in Opposition to Plaintiffs’ Motion for Summary Judgment, at *1, Ass’n of 
Molecular Pathology v. U.S. Pat. & Trademark Office, 702 F. Supp. 2d 181, 185 (S.D.N.Y. 
2010), aff’d in part, No. 2010–1406, 2011 WL 3211513 (Fed. Cir. July 29, 2011). 
108.  The names BRCA1 and BRCA2 stand for Breast Cancer Susceptibility Gene 1 
and Breast Cancer Susceptibility Gene 2.   
109.  Ass’n of Molecular Pathology v. U.S. Pat. & Trademark Office, 702 F. Supp. 2d 
181, 185 (S.D.N.Y. 2010), aff’d in part, No. 2010–1406, 2011 WL 3211513 (Fed. Cir. July 29, 
2011). 
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inform women as to whether they are at a heightened risk of developing 
these cancers.  In March of 2010, the Southern District of New York 
addressed the validity of composition-of-matter and method patents 
relating to these genes in Association for Molecular Pathology v. United 
States Patent and Trademark Office110 and invalidated fifteen patents 
associated with the BRCA1 and BRCA2 genes.  On July 29, 2011, the 
Federal Circuit Court of Appeals ruled on the case, overturning much of 
the lower court’s decision.  The Federal Circuit reversed the lower 
court’s decision as to Myriad’s patents on the isolated BRCA1 and 
BRCA2 genes, but affirmed the lower court’s finding that all but one of 
the method patents tied to BRCA1 and BRCA2 were invalid.111 
Breast cancer is currently the most frequently diagnosed cancer 
worldwide and the second leading cause of cancer deaths for women in 
the United States.112  In the 1990s, a group of researchers discovered that 
the BRCA1 and BRCA2 genes correlated with an increased risk of 
breast and ovarian cancer.113  A woman’s risk of developing breast or 
ovarian cancer dramatically rises if she has inherited a deleterious 
BRCA1 or BRCA2 mutation.  Women carrying inherited mutations on 
their BRCA1 and BRCA2 genes can face up to an 85% cumulative risk 
of breast cancer and up to a 50% cumulative risk of ovarian cancer.114  
Harmful BRCA1 mutations may also increase a patient’s risk of 
developing cervical, uterine, pancreatic, and colon cancer,115 while 
harmful BRCA2 mutations have been linked to an increased risk of 
pancreatic cancer, stomach cancer, and melanoma.116  Based on these 
findings, Myriad Genetics, a company which had participated in the 
research to isolate and sequence the genes, developed a diagnostic test 
to detect the presence of mutations on the BRCA1 and BRCA2 genes 
in order to aid women and physicians when making prognostic 
decisions.  The University of Utah and Myriad Genetics obtained the 
patents to the BRCA1 and BRCA2 genes between 1995 and 1998.117  
 
110.  Id. at 200. 
111.  Ass’n of Molecular Pathology v. U.S. Pat. & Trademark Office, 653 F.3d 1329, 
1331 (Fed. Cir. 2011). 
112.  Ass’n of Molecular Pathology, 702 F. Supp. 2d at 200 (citing Parthasarathy Decl. 
¶ 8).   
113.  Id. at 201–02.   
114.  Id. at 203 (citing Love Decl. ¶ 10).   
115.  Luna Kadouri, Ayala Hubert, et al., Cancer Risks in Carriers of the BRCA1/2 
Ashkenazi Founder Mutations, 44 JOURNAL OF MEDICAL GENETICS 467, 467–71 (2007). 
116.  The Breast Cancer Linkage Consortium, Cancer risks in BRCA2 mutation 
carriers, 91 JOURNAL OF THE NATIONAL CANCER INSTITUTE 15, 1310 (1999). 
117.  Ass’n of Molecular Pathology, 702 F. Supp. 2d at 202–06. 
RUSSELL- FORMATTED (DO NOT DELETE) 11/15/2011  11:09 AM 
100  MARQ. INTELL. PROP. L. REV. [Vol. 16:1 
 
The ability to determine whether a patient carries inherited mutations 
of the BRCA1/2 genes offers tremendous benefits in the provision of 
medical care to them.  Determining whether a woman carries inherited 
mutations of either of these genes can be of critical importance in 
informing her prognosis and potentially providing her with life-saving 
preventative measures.  Knowing whether a woman is a carrier of 
BRCA1 or BRCA2 genetic mutations allows her and her physician to 
make more informed decisions about her health and body.  Women who 
carry a BRCA1/2 genetic mutation have a range of options for 
managing their risk of cancer, including increased surveillance, 
prophylactic surgery, chemoprevention, and risk avoidance.  Likewise, a 
woman who has been diagnosed with breast cancer may opt for a more 
aggressive course of treatment if she carries the BRCA1 and BRCA2 
mutations and is therefore at heightened risk of recurrence. 
Unfortunately, as the patent-holder and sole provider of the 
BRCA1/2 tests, Myriad’s enforcement of its patents highlighted several 
of the criticisms commonly leveled against gene patents.  Many women 
were prevented from determining whether they were carriers of the 
mutations because the genes have been patented by Myriad Genetics.  
As the monopoly-holder over the diagnostic tests, Myriad Genetics was 
able to charge upwards of $3,000 a test, a cost which proved prohibitive 
for many women.  Myriad Genetics also refused to license the diagnostic 
tests to other laboratories,118 which in many cases prevented women 
from obtaining a second opinion in order to confirm or clarify 
ambiguous test results. 
In 2008, several doctors’ groups, together with the ACLU and Public 
Patent Foundation, filed a lawsuit in the Southern District of New York 
seeking to invalidate Myriad Genetics’ patents on BRCA1 and BRCA2.  
Citing a litany of complaints, the plaintiffs claimed that “Myriad’s 
patents and its position as the sole provider of BRCA1/2 testing has 
hindered the ability of patients to receive the highest-quality breast 
cancer genetic testing and has impeded the development of 
improvements to BRCA1/2 genetic testing.”119  The plaintiffs argued 
that Myriad’s monopoly had resulted in less comprehensive and lower 
test qualities, and prevented many patients from determining whether 
they had these mutations before making potentially life-altering medical 
decisions.120 
 
118.  Id.  
119.  Id. at 206 (emphasis removed). 
120.  Id.  
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The plaintiffs challenged the validity of several different types of 
gene patents owned by Myriad Genetics, arguing that they were invalid 
under 35 U.S.C. § 101.  The patents challenged included both: (1) 
composition of matter gene patents of “isolated and purified” DNA 
sequences; and (2) diagnostic gene patents involving methods of 
analyzing or comparing the DNA sequences of the BRCA1/2 genes to 
detect mutations.  In March 2010, the Southern District of New York 
ruled in favor of the plaintiffs and invalidated fifteen claims made in the 
seven patents relating to the BRCA1 and BRCA2 breast cancer genes.121  
In July of 2011, the Federal Circuit reversed the district court’s decision 
and found that claims covering isolated DNA sequences are patentable 
subject matter under 35 U.S.C. § 101.  However, the Federal Court 
affirmed the lower court’s ruling with respect to the diagnostic genetic 
patents, finding all but one of Myriad’s method claims were directed to 
patent-ineligible, abstract mental process, and fail the machine-or-
transformation test.122 
The challenged diagnostic gene patents claimed the method of 
diagnosing whether an individual carried the BRCA1/2 genetic 
mutations and was therefore at a heightened risk of developing breast 
or ovarian cancer.  For example, Claim 1 of the ‘999 patent was directed 
to the process of “analyzing” a BRCA1 sequence in order to determine 
whether or not a specified naturally-occurring mutations exists.”123  The 
process was not limited to any particular method of analysis and did not 
specify any further action beyond the act of “analyzing.”124  Likewise, 
other claims, such as claims 1 of the ‘001, ‘441, and ‘857 patents, were 
directed to “comparing” two gene sequences to determine whether any 
differences existed and failed to specify any limitations on the method 
of comparison.125  Following is a brief excerpt of the language from one 
of the contested patents, claim 1 of ‘857: 
A method for identifying a mutant BRCA2 nucleotide sequence 
in a suspected mutant BRCA2 allele which comprises comparing 
the nucleotide sequence of the suspected mutant BRCA2 allele 
with the wild-type BRCA2 nucleotide sequence, wherein a 
difference between the suspected mutant and the wild-type 
 
121.  See generally id. at 181. 
122.  Ass’n of Molecular Pathology v. U.S. Pat. & Trademark Office, 653 F.3d 1329, 
1356 (Fed. Cir. 2011).   
123.  Ass’n of Molecular Pathology, 702 F. Supp. 2d at 233. 
124.  Id. 
125.  Id. 
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sequence identifies a mutant BRCA2 nucleotide sequence.126 
At the time of its decision, the district court relied on the “machine-
or-transformation” test in assessing the validity of the diagnostic gene 
patents at issue.127  Relying heavily on the Federal Circuit’s analysis in 
Bilski as to what constitutes a transformation, the court held that the 
diagnostic gene patents at issue did not involve any transformation and 
therefore were non-patentable subject matter.  In particular, the court 
held that the addition of a data-gathering step was insufficient to 
convert a series of steps into a patentable process,128 and emphasized 
that the “transformation must be central to the purpose of the claimed 
process.”129  The court noted that  “the inherent step of gathering data 
can also fairly be characterized as insignificant extra-solution activity.”130  
To hold otherwise, the court reasoned, would place a meaningless limit 
on patent claims, as “a requirement simply that data input be gathered - 
without specifying how - is a meaningless limit on a claim to an 
algorithm because every algorithm inherently requires the gathering of 
data inputs.”131  The court concluded that diagnostic gene patents “seek 
to claim a non-transformative process that encompasses [a fundamental 
principle] without the aid of . . . any other device.”132  This past July, the 
Federal Court affirmed the lower court’s ruling with respect to the 
diagnostic genetic patents, finding all but one of Myriad’s method claims 
were directed to patent-ineligible, abstract mental process, and failed 
the machine-or-transformation test.133 
The Federal Circuit agreed that “all but one of Myriad’s claims are 
directed to patent-ineligible abstract mental processes, and fail the 
machine-or-transformation test.”134  The court rejected Myriad’s 
argument that its methods of “comparing” or “analyzing” BRCA 
sequences satisfy the machine-or-transformation test as outlined in 
Prometheus because each requires extracting and sequencing a human 
 
126.  U.S. Patent No. 6,033,857 claim 1 (filed on Mar. 20, 1998).   
127.  See generally Ass’n of Molecular Pathology, 702 F. Supp. 2d at 181. 
128.  Id. at 233 (“[A]dding a data-gathering step to an algorithm is insufficient to 
convert that algorithm into a patent-eligible process.”) (citing In re Bilski, 545 F.3d at 963). 
129.  Id. (citing In re Bilski, 545 F.3d at 962).   
130.  Id. (citing Flook, 437 U.S. at 590).   
131.  Id. (citing In re Grams, 888 F.2d at 839–40 (Fed. Cir. 1989)). 
132.  In re Bilski, 545 F.3d at 965.  
133.  Ass’n of Molecular Pathology v. U.S. Pat. & Trademark Office, 2011 WL 
3211513, at *20 (July 29, 2011).   
134.  Id.   
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sample before the sequences can be analyzed.135  The court held that the 
method claims lacked any “necessarily transformative step” and, in the 
end, “recite nothing more than the abstract mental steps necessary to 
compare two different nucleotide sequences.”136  The court ruled that 
the claims themselves did not include those steps, and the steps of 
“comparing” and “analyzing” could not be read to imply that 
“extracting” or “sequencing” need also be conducted.  The Federal 
Circuit concluded that because the process of comparing and analyzing 
could be “accomplished by mere inspection alone,”137 Myriad’s claims 
failed the machine-or-transformation test, and were directed to 
patentable abstract mental processes. 
The court was right to find diagnostic patents equally undeserving of 
patent protection under the standards outlined in Bilski v. Kappos.  As 
was affirmed by the Supreme Court, a patent cannot foreclose all 
“practical application” of a fundamental principle.138  Considered as a 
whole, diagnostic gene patents cover a phenomenon of nature - whether 
two genetic sequences are different or the same.  The claims exemplify 
how a patent on a general correlation can monopolize a law of nature.  
Furthermore, placing insignificant limitations on a fundamental 
principle will not transform it into a patentable process, and neither will 
post-solution activity transform an unpatentable principle into a 
patentable process.  In the case of genetic diagnostic tests, the isolation 
and sequencing of DNA from a human sample, when incorporated into 
the diagnostic genetic patents, represents nothing more than a data-
gathering step.  Thus, the sole difference between the claims seeking 
patent protection and the correlation is the inclusion of this insignificant 
data-gathering step, and “insignificant extra-solution activity will not 
transform an unpatentable principle into a patentable process.”139  
Furthermore, although the process must be considered as a whole, the 
“inventive concept” of the process should not derive solely from the 
fundamental principle.  In the case of genetic diagnostics, the inventive 
concept derives solely from the natural correlation, whereas the process 
utilizing it offers no new or useful end. 
The problems raised by granting a monopoly over diagnostic 
 
135.  Prometheus Labs. v. Mayo Collaborative Srvs., 628 F.3d 1347 (Fed. Cir. 2010), 
cert. granted, 131 S. Ct. 3027. 
136.  Ass’n of Molecular Pathology v. U.S. Pat. & Trademark Office, 353 F.3d 1329, 
1336 (Fed. Cir. 2011). 
137.  Id. at 22.   
138.  Diamond v. Diehr, 450 U.S. 175, 189–86 (1981) (citing Benson, 409 U.S. 63). 
139.  Id. at 191–92.   
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methods were highlighted in the case of Metabolite Laboratories, Inc. v. 
Laboratory Corp. of America Holdings, in which the Federal Circuit 
upheld the patentability of a diagnostic patent claim for a vitamin B 
deficiency.140  The claim in Metabolite Labs was directed at correlating 
elevated levels of total homocysteines in patients’ blood to vitamin B 
deficiencies,141 which can cause serious illnesses including cognitive 
dysfunction, birth defects and cancer, and was very similar in form to 
the claims raised in Molecular Pathology.142  The claim did not specify 
any particular procedure for performing the measurement,143 and 
respondents argued that the patent created a protected monopoly over 
the process of ‘correlating’ test results and potential vitamin 
deficiencies.  LabCorp filed a petition for certiorari to the Supreme 
Court, questioning “[w]hether a method patent . . . directing a party 
simply to ‘correlat[e]’ test results can validly claim a monopoly over a 
basic scientific relationship . . . such that any doctor necessarily infringes 
the patent merely by thinking about the relationship after looking at a 
test result.”144 
In a dissenting opinion to the dismissal of certiorari, Breyer cogently 
outlined the problems raised by diagnostic patents.  Discussing the 
merits of the underlying case, Breyer noted that Metabolite 
Laboratories “cannot avoid the fact that the process is no more than an 
instruction to read some numbers in light of medical knowledge.”145  
Breyer went on to explain that although, “[o]ne might, of course, reduce 
the ‘process’ to a series of steps, e.g. Step 1: gather data; Step 2: read a 
number; Step 3: compare the number with the norm; Step 4: act 
accordingly.  But one can reduce any process to a series of steps.  The 
question is what those steps embody.”146  As Breyer aptly pointed out, 
“Claim 13’s process instructs the user to (1) obtain test results and (2) 
think about them.”147  Breyer further likened the diagnostic correlation 
at issue with the unpatentable algorithm in Flook because the subject 
matter at issue in both cases, and as in this case, was a “simple natural 
 
140.  Metabolite Labs. Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1368 (Fed. 
Cir. 2004). 
141.  Id. at 1358–59. 
142.  Id. at 1358.   
143.  Id. at 1358–59. 
144.  Petition for a Writ of Certiorari, Lab. Corp. of Am. Holdings v. Metabolite Labs., 
Inc., 370 F.3d 1354 (2004) (No. 04-607), 2004 WL 2505526 (limiting grant of certiorari to issue 
three only). 
145.  Lab. Corp. of Am. Holdings, 548 U.S. at 137 (Breyer, J., dissenting).  
146.  Id. at 137 (Breyer, J., dissenting). 
147.  Id. at 136 (Breyer, J., dissenting).  
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correlation, i.e. a ‘natural phenomenon.’”148  Similarly, the claims in 
Molecular Pathology were directed to correlating two gene sequences to 
determine whether any differences existed and failed to identify any 
limitations on the method of comparison.149  Diagnostic methods consist 
of little more than plugging a variable into a formula. 
D. Patents on Mixed Diagnostic-Therapeutic 
A more difficult issue is raised by patents on diagnostic methods that 
also potentially involve therapeutic applications.  In Association for 
Molecular Pathology, the only method claim that the Federal Circuit 
found to be patentable subject matter was a method claim for screening 
potential cancer therapeutics by analyzing growth rates of cells with 
altered BRCA genes in the presence or absence of the treatments.  The 
court reasoned that Myriad’s method claim was “not so ‘manifestly 
abstract’ as to claim only a scientific principle.”150  The court also held 
that the method claim passed the machine-or-transformation test, since 
it involved the steps of “growing” transformed cells in the presence or 
absence of a potential cancer therapeutic, and “determining” the cells’ 
growth rates.  Because the court found these steps to be “inherently 
transformative,” they found that the claimed process covered patentable 
subject matter under § 101. 
In arguing that the method claim satisfied the “machine-or-
transformation” test and constituted patentable subject matter, the 
Federal Circuit looked at cases involving patents on diagnostic methods 
that also involve therapeutic applications, such as was the case in 
Prometheus Laboratories, Inc., v. Mayo Collaborative Servs.151  In 
arguing that their diagnostic gene patents satisfied the “machine-or-
transformation” test, Myriad leaned heavily on an earlier decision of the 
Federal Circuit involving advanced diagnostic method patents - 
Prometheus Labs, Inc., v. Mayo Collaborative Servs.152  Prometheus 
involved a patent claim directed to methods for calibrating the proper 
dosage of a drug by measuring metabolites in subjects having 
 
148.  Id. at 137 (Breyer, J., dissenting). 
149.  Ass’n of Molecular Pathology v. U.S. Pat. & Trademark Office, 702 F. Supp. 2d 
181, 233 (S.D.N.Y. 2010). 
150.  Ass’n of Molecular Pathology v. U.S. Pat. & Trademark Office, 653 F.3d 1329, 
1358 (Fed. Cir. 2011).   
151.  Prometheus Labs., Inc. v. Mayo Collaborative Servs., 581 F.3d 1336 (Fed. Cir. 
2009), cert. granted, judgment vacated, and remanded, 130 S. Ct. 3543 (2010). 
152.  Id. 
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gastrointestinal disorders.153  Patients battling autoimmune diseases, 
such as Crohn’s disease, can suffer debilitating symptoms.  Although 
there are drugs that treat these diseases by suppressing the body’s 
natural immune system, they can carry serious, potentially fatal, side-
effects if the dosage is too high for a given patient.  Based on the 
correlation between metabolite levels in a patient’s blood and the 
therapeutic efficacy of a dose of the drug, the patentees in Prometheus 
claimed the process of optimizing therapeutic efficiency by determining 
metabolite levels in order to identify a need to adjust drug dosages 
either upwards or downwards based on those levels.154  Prometheus is 
the sole licensee of two methods for calibrating the proper dosage of 
drugs. 
Claim 1 of the 302 patent claims: 
A method of optimizing therapeutic efficacy for treatment of an 
immune-mediated gastrointestinal disorder, comprising: (a) 
administering a drug providing 6-thioguanine to a subject having 
said immune-mediated gastrointestinal disorder; and (b) 
determining the level of 6-thioguanine in said subject having said 
immune-mediated gastrointestinal disorder, wherein the levels of 
6-thioguanine less than about 230 pmol per 8x10 red blood cells 
indicates a need to increase the amount of said drug 
subsequently administered to said subject and wherein the levels 
of 6-thioguanin greater than about 400 pmol per 8x10 red blood 
cells indicates a need to decrease the amount of said drug 
subsequently administered to said subject.155 
The issue was whether the claimed methods for individually 
calibrating the appropriate dosages of synthetic drugs for treatment for 
patients with various autoimmune diseases constituted unpatentable 
“natural phenomena.” 
Prior to Bilski, the Federal Circuit held “that the relevant 
transformation for purposes of the ‘machine or transformation’ test was 
the transformation of the human body as well as the chemical and 
physical changes of the drug’s metabolites”156 and concluded that the 
process was patentable.  On remand, the Federal Circuit reaffirmed its 
earlier ruling, holding not only that Prometheus’s asserted claims recite 
 
153.  Id. at 1343–50.   
154.  Id. at 1339–40.   
155.  U.S. Patent No. 6,680,302 (filed on Dec. 27, 2001). 
156.  Prometheus Labs., Inc., 581 F.3d at 1346.   
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transformative “administering” and “determining” steps, but also that 
Prometheus’s claims are drawn not to a law of nature, but to a particular 
application of naturally occurring correlations, and accordingly do not 
preempt all uses of the recited correlations between metabolite levels 
and drug efficacy or toxicity.157  As such, the court found that the claims 
did not preempt all uses of the natural correlations; but rather utilized 
them in a series of specific steps.158 
Both Prometheus and Association for Molecular Pathology misread 
Supreme Court precedent.  The prohibition against patenting abstract 
ideas “cannot be circumvented by attempting to limit the use of the 
formula to a particular technological environment” or adding 
“insignificant post-solution activity.”159  A patent application cannot 
immunize a claim merely by tying it to a particular application, if that 
particular application is obvious and nothing useful or new has been 
added.  To hold otherwise would allow patent holders to appropriate 
rights to fundamental principles bit by bit.  Under the governing 
preemption standard, both claims are invalid because they preempt all 
practical use of naturally occurring correlations and any machine or 
transformation present in the claims is merely insignificant post-solution 
activity.160 
This past June, the Supreme Court accepted certiorari in 
Prometheus on the patentable subject matter eligibility of medical 
diagnostic methods.  The issue raised on appeal, which emphasized the 
preemption standard, stated:  
Whether 35 U.S.C. § 101 is satisfied by a patent claim that covers 
observed correlations between blood test results and patient 
health, so that the claim effectively preempts all uses of the 
naturally occurring correlations, simply because well-known 
methods used to administer prescription drugs and test blood 
may involve “transformations” of body chemistry. 
In both Prometheus and Association for Molecular Pathology, the 
 
157.  Prometheus Labs., Inc. v. Mayo Collaborative Servs., 628 F.3d 1347, 1355 (Fed. 
Cir. 2010). 
158.  Id. (citing Diamond v. Diehr, 450 U.S. 175, 187 (1981)) (stating that “[t]heir 
process admittedly employs a well-known mathematical equation, but they do not seek to 
preempt the use of that equation. Rather, they seek only to foreclose from others the use of 
that equation in conjunction with all of the other steps in their claimed process.”). 
159.  Diehr, 450 U.S. at 191–92. 
160.  Prometheus Labs., Inc., 628 F.3d at 1354. 
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presence of transformations and machines is irrelevant.  Rather, 
patentability under § 101 should instead depend on whether the claims 
“recite” and “wholly preempt” some natural phenomenon.161  Dissecting 
the methods into their component parts, the claimed transformations 
should be disregarded because they are “conventional method steps” 
(i.e., not novel) or “merely data-gathering steps,” and the final step can 
“be ignored because it was ‘only a mental step.’”162 
The ruling in Prometheus and Association for Molecular Pathology 
serves as an invitation to patent lawyers to attempt to bring abstract 
ideas within the penumbra of patentable subject matter simply by 
including technical details in the claim themselves.  Additionally, 
attempting to distinguish the claims because they may have therapeutic 
effects threatens to allow all types of fundamental principles under 
patent protection provided that the claim language is framed as a 
“method of treatment.”  To find these claims deserving of patent 
protection based on an admonition to pursue an appropriate course of 
treatment in light of test results would threaten to protect all diagnostic 
patents from review by simply appending a similar admonition. 
IV. POLICY ARGUMENTS AGAINST DIAGNOSTIC GENETIC PATENTS 
Finally, in rejecting the machine-or-transformation test, it is 
important to remember that Bilski emphasized that relying on rigid tests 
risks “obscuring the larger object of securing patents for valuable 
inventions without transgressing the public domain.”163  The Court went 
on to reiterate that “patent law faces a great challenge in striking the 
balance between protecting inventors and not granting monopolies over 
procedures that others would discover by independent creative 
application of general principles.”164  For that reason, when deciding on 
what the patent laws should cover, one should balance between over- 
and under-protection, that is to say, perform a cost-benefit analysis.  
There are sound policy decisions for excluding advanced diagnostics 
from patent protection.  While, generally, patent protection encourages 
research and development, several convincing arguments have been 
advanced that the goals of research and development are undermined in 
the case of diagnostic patents.  In the case of diagnostic genetic patents, 
the cost-benefit analysis weighs in favor of not granting patent 
 
161.  Id. at 1351. 
162.  Id. at 1352. 
163.  Bilski v. Kappos, 130 S. Ct. 3218, 3227, 3228 (2010). 
164.  Id. at 3228.   
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protection to diagnostic methods. 
A. Advanced Diagnostics Patents Are Unnecessary to Motivate 
Innovation 
Patent law aims to protect inventors while at the same time not 
granting monopolies over procedures that others would have been 
independently discovered through the application of general well-
known principles.165  Thus, one of the central constitutional questions 
involves determining whether a patent monopoly is in fact necessary to 
motivate innovation.166  This question necessitates a nuanced calculus as 
“[b]oth common sense and recent economic scholarship suggest that 
the[] dynamics of cost, risk, and reward vary by the type of thing being 
patented.”167  Undoubtedly, “[i]f a high enough bar is not set when 
considering patent applications . . . patent examiners and courts could 
be flooded with claims that would put a chill on creative endeavor and 
dynamic change.”168  Patents provide the ability to extract monopoly 
rent and, in some cases, those rents may be beyond what is necessary to 
encourage innovation.  Overbroad and unnecessary patent protection 
comes with very real costs, both to consumers and innovation. 
Because the very objective of patent protection is to promote 
innovation,169 in assessing the wisdom of patent protections, it is 
important to question “whether a patent monopoly is necessary to 
‘motivate the innovation.’”170  Patents motivate innovation in two 
principal ways, by stimulating research and innovative activities, and by 
stimulating investment to commercially develop promising inventions.  
Patents on diagnostic methods are largely unnecessary to create 
incentives either for initial discoveries of diagnostic tests or for the 
development of commercial applications of diagnostic tests once 
discovered.171  Indeed, the Medical Procedure Patent Coalition argues 
that the patent “incentive” is unnecessary in medical practice, as “the 
development of new medical procedures often occurs in the normal 
course of medical practice and generally does not require significant 
 
165.  Id.  
166.  Id. at 3253 (citing Pfaff v. Wells Electronics, Inc., 525 U.S. 55, 63 (1998)).   
167.  Id.   
168.  Id. at 3229. 
169.  See U.S. CONST. art. 1, § 8, cl. 8.   
170.  Bilski, 130 S. Ct. at 3253 (citing Pfaff v. Wells Electronics, Inc., 525 U.S. 55, 63 
(1998)).   
171.  Ass’n of Molecular Pathology v. U.S. Pat. & Trademark Office, 702 F. Supp. 2d 
181, 210 (S.D.N.Y. 2010) (citing Cho Decl. ¶ 25; Leonard Decl. ¶¶ 20–21). 
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capital investment.”172 
The findings from a Report of the Secretary’s Advisory Committee 
on Genetics, Health, and Society Draft emphasizes that patents offer 
minor, if any at all, stimulus to the development of genetic diagnostics.  
As to incentivizing innovation, the report found that 
[T]he prospect of patent protection of a genetic research 
discovery does not play a significant role in motivating scientists 
to conduct genetic research.  Scientists typically are driven 
instead by factors such as the desire to advance understanding, 
the hope of improving patient care through new discoveries, and 
concerns for their own career advancement.173 
Thus, patents are not necessary to motivate the innovation of 
advanced medical diagnostics, as medical practitioners already have 
sufficient incentives to provide patients with the best possible care.  
Furthermore, in determining whether a patent monopoly is, in fact, 
necessary to “motivate the innovation”,174 courts should consider 
whether the discovery is one that has historically been afforded patent 
protection.  Diagnoses have not historically been eligible to receive the 
protection of the patent laws.  In fact, the first 150 years of patent 
jurisprudence in this country did not recognize the patentability of 
medical procedures, treatments, or methods of diagnosis.175  
Nonetheless, the medical and scientific communities have made great 
strides in the field of diagnostics in that time.  Additionally, the majority 
of the research tied to genetic diagnostics is funded by the government 
or universities, not private investors.  A study of patents issued for 
genetic diagnostics in the U.S. revealed that 67% of the patents were 
issued for discoveries that were in fact funded by the U.S. government, 
not by private investors.176 
Patents are also largely unnecessary to stimulate investment to 
 
172.  Jenner & Block, Patents for Surgical/Medical Procedures: A Call for Legislative 
Prohibition, available at http://www.ascrs.org/ (last visited at August 1, 2011). 
173.  Gene Patents and Licensing Practices and Their Impact on Patient Access to 
Genetic Tests, Rep. of the Secretary’s Advisory Committee on Genetics, Health, and Society, 
at 1 (Apr. 2010) [hereinafter SACGHS Report].   
174.  Bilski, 130 S. Ct. at 3253 (citing Pfaff v. Wells Electronics, Inc., 525 U.S. 55, 63 
(1998)). 
175.  Robert M. Portman, Legislative Restriction on Medical and Surgical Procedure 
Patents Removes Impediment to Medical Progress, 4 U. BALT. INTELL. PROP. L.J. 91, 92 
(1996).   
176.  Ass’n of Molecular Pathology, 702 F. Supp. 2d at 210 (citing Cho Decl. ¶ 22). 
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commercially develop diagnostic tests once discovered.  As opposed to 
many pharmaceutical patents, the benefits of diagnostic discoveries 
generally require minimal capital expenditures to bring them to market 
once discovered.  These discoveries often entail basic scientific 
principles that can be immediately applied by laboratories and medical 
facilities.  As opposed to therapeutics, in which bringing products to 
market may require significant investment in order to obtain FDA 
approval and navigate the regulatory system, in the case of the 
diagnostic patents, there are generally minimal costs associated with 
bringing these discoveries to market.  Often all that is required is 
publication.  The SACGHS Report emphasizes that “[d]evelopment 
barriers generally do not appear to pose a significant barrier for 
bringing new diagnostic tests on-line.  When a gene sequence is 
reported, diagnostic testing quickly arises regardless of patent status to 
meet clinical need.”177  Furthermore, “the fact that unpatented genetic 
discoveries [are] routinely developed into clinical genetic tests suggests 
that patents are not needed for development of these tests.”178  Thus, the 
need to incentivize commercial development of diagnostic tests is 
lacking, as genetic diagnoses are easily performed once a gene has been 
sequenced.179  “[W]hereas biotechnology patents may well be necessary 
to ensure the commercial viability of the development of gene therapies 
(in analogy to pharmaceuticals), molecular diagnostics are more easily 
developed.”180 
Thus, patent rights appear largely unnecessary in order to encourage 
clinicians and scientists to develop new diagnostic methods.  Clinical 
need appears to be a sufficient motivator to incentivize development of 
new diagnostic tests, and once discovered, the investment to 
commercially develop these discoveries is minimal. 
 
177.  SACGHS Draft Report, supra note 173, at 439. 
178.  Id.   
179.  Mildred K. Cho, Effects of Patents and Licenses on the Provision of Clinical 
Genetic Testing Services, 5 J. MOLECULAR DIAGNOSTICS 3 (2003) (discussing one study that 
found that many laboratories offered testing for genes based on published sequence data, 
before any commercial kits were made available).   
180.  Gregory P. Lekovic, Genetic Diagnosis and Intellectual Property Rights: A 
Proposal to Amend “The Physician Immunity Statute”, 4 YALE J. HEALTH POL’Y, L. & 
ETHICS 275, 298 (2004) (“The timeline for scientific development and regulatory approval of 
diagnostics is shorter than for therapeutics and the process, overall, is less expensive.  
However, the revenue potential is smaller for diagnostics than for therapeutics for several 
reasons, including greater price sensitivity.”  See, e.g., Robert S. Schifreen, Molecular 
Diagnostics: The Challenge for the Future, IVD TECH., Nov. 2003, at 27). 
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B. Upstream and Downstream Effects of Genetic Diagnostic Patents 
Not only are genetic patents unnecessary to motivate innovation, 
they may actually stymie research and development.  Certain types of 
gene patents threaten to impede scientific progress,181 as much of the 
advancement of scientific research into the human genome depends on 
a free-flow exchange of information.  Free access to data is of critical 
importance to the future of genetic discoveries.182  Thus, while the goal 
of patents should be to incentivize and reward the development of new 
knowledge and techniques, gene patents can paradoxically lead to a 
decrease in scientific advances. 
As has been pointed out, “as patent applicants push the quest for 
patents further and further upstream, particularly in the biotechnology 
field, the impact of such patent grants has become increasingly 
troubling.”183  Gene patents may contribute to a phenomenon known as 
the “tragedy of the anti-commons.”184  In the “tragedy of the anti-
commons”, competing patent rights held by independent parties prevent 
any one party from engaging in productive innovation.185  In effect, the 
presence of patents leads to an underutilization of resources because the 
intellectual property rights 
[D]iscourage research by impeding the free exchange of 
information, for example by forcing researchers to avoid the use 
of potentially patented ideas, by leading them to conduct costly 
and time-consuming searches of existing or pending patents, by 
requiring complex licensing arrangements, and by raising the 
costs of using the patented information, sometimes 
prohibitively.186 
In this way, patent protection may ultimately undermine the very 
goals it seeks to promote.  While the existence of the “anticommons is 
 
181.  Ass’n for Molecular Pathology, 702 F. Supp. 2d at 208. 
182.  Id.  
183.  Harry First, Controlling the Intellectual Property Grab: Protect Innovation, Not 
Innovators, 38 RUTGERS L.J. 365, 381 (2007).   
184.  Id.  
185.  See, e.g., Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter 
Innovation? The Anticommons in Biomedical Research, 280 SCIENCE 698 (1998) (citing 
Michael A. Heller, The Tragedy of the Anticommons: Property in the Transition from Marx to 
Markets, 111 HARV. L. REV. 621 (1998)).   
186.  Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S. 124, 127 (2006) 
(Breyer, J., dissenting).   
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highly disputed with respect to intellectual property,”187 in the case of 
gene patents, the “tragedy of the anti-commons” is supported by 
empirical research.  One survey of laboratory directors found that 53% 
had decided against developing new clinical tests because of existing 
gene patents, and 67% believed that gene patents impeded their ability 
to conduct research.188  In particular, some studies have noted that 
patents appear to be more problematic in the area of DNA diagnostics 
than in other fields of biomedical research,189 and that diagnostic 
laboratories have been the most critical of the impact of patents on gene 
sequences and products.190 
The potential chilling effect of gene patents is particularly prevalent 
in determining variations of unknown significance (“VUS”) within 
genes.  By way of example, the monopoly over the BRCA1 and BRCA2 
genes has hindered other laboratories and scientists from determining 
the meaning of VUSs tied to breast and ovarian cancer and prevented a 
better understanding of those genes.191  One study found that Myriad 
Genetics’ breast cancer gene patents negatively impacted the public 
knowledge of those genes by as much as five to ten percent.192 
For example, if genetic testing reveals a mutation in a gene that has 
not previously been associated with any diseases in other individuals, 
the person’s test result may be interpreted as ambiguous (VUS).  One 
study found that ten percent of women who underwent BRCA1/2 
testing received an ambiguous result.193  Because people have genetic 
differences that are not associated with an increased risk of diseases, it is 
 
187.  Richard A. Epstein & Bruce N. Kuhlik, Is There a Biomedical Anticommons?, 27 
REG. 54 (2004).   
188.  Ass’n of Molecular Pathology v. U.S. Pat. & Trademark Office, 702 F. Supp. 2d 
181, 208 (S.D.N.Y. 2010) (citing Cho Decl. ¶ 10).   
189.  Rebecca S. Eisenberg, Noncompliance, Nonenforcement, Nonproblem? 
Rethinking the Anticommons in Biomedical Research, 45 HOUS. L. REV. 1059, 1071 (2008) 
(citing John P. Walsh, Ashish Arora & Wesley M. Cohen, Effects of Research Tool Patents 
and Licensing on Biomedical Innovation, in PATENTS IN THE KNOWLEDGE-BASED 
ECONOMY 285, 317–19 (2003)).  
190.  Eisenberg, supra note 189, at 1069 (citing Dianne Nicol & Jane Nielsen, Patents 
and Medical Biotechnology: An Empirical Analysis of Issues Facing the Australian Industry 
64-71 (Univ. of Tasmania Ctr. For Law and Genetics, Occasional Paper No. 6, 2003), 
available at http://www.lawgenecentre.org/Publication%20PDF/OccPaper%206.pdf (“noting 
that 77% of respondents from diagnostic facilities stated that patents on gene sequences have 
a negative impact and 69% stated that patents on gene products have a negative impact”)).   
191.  Ass’n of Molecular Pathology, 702 F. Supp. 2d at 208 (citing Cho Decl. ¶ 10). 
192.  Id. (citing Murray Decl. ¶¶ 7–15, 20). 
193.  Beth N. Peshkin et al., BRCA1/2 Testing: Complex Themes in Result 
Interpretation, 19 J. OF CLINICAL ONCOLOGY 2555, 2560 (2001). 
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often unclear whether a specific DNA mutation will affect a person’s 
risk of developing a disease.  The more research that is conducted and 
the more people are tested for BRCA1 or BRCA2 changes, the more 
scientists will learn about variations of unknown significance. 
Moreover, the negative effects of gene patents are likely to escalate.  
Currently, the majority of diagnostic genetic testing involves direct 
correlations between a particular gene and the corresponding disease, 
i.e. Tay-Sachs, Huntingtons, BRCA1/2.  In these cases, a disease (often 
a rare one) will map directly onto one particular gene.194  However, as 
scientific knowledge of the human genome improves, it will become 
increasingly possible to correlate diseases to combinations of different 
genes.  Gene patents threaten to impede this research by blocking the 
collaborative efforts of researchers.  This problem has been referred to 
as a “patent thicket” - a “dense web of overlapping intellectual property 
rights that a company must hack its way through in order to actually 
commercialize new technology.”195  As of yet, the potential negative 
effects of these “patent thickets” have not yet fully manifested, as the 
current state of diagnostic testing predominantly focuses on discrete 
genes.  However, in the future, many scientific advances may depend 
upon the testing on multiple genes - the rights of which may be owned 
by numerous different companies.  As the scientific community moves 
towards an increased use of the genome to inform diagnostic and 
therapeutic decisions, the existence of gene patents threaten to 
roadblock these advances.  The owner of one gene patent would be able 
to effectively block an entire line of research or clinical testing.  As 
scientific research progresses, the number of overlapping, or stacked, 
patents on genes will likely increase.  “Since many ‘stacked’ patents on 
the same disease gene will increase the licensing costs of the diagnostic 
test, it is possible, if not likely, that gene-based diagnostic tests will be 
kept out of the market not by scientific obstacles, but rather by 
commercial ones.”196 
 
194.  See NATIONAL TAY-SACHS & ALLIED DISEASE ASSOCIATION, INC., 
http://www.ntsad.org/ (last visited Aug. 1, 2011) (stating that genetic diseases often have 
higher incidence rates in genetically isolated populations).  For example, Ashkenazi Jews 
have a heightened risk of suffering from Tay-Sachs, Canavan’s disease, among other 
disorders.   
195.  Carl Shapiro, Navigating the Patent Thicket: Cross Licenses, Patent Pools, and 
Standard Setting, 1 INNOVATION POL’Y & ECON. 119, 120–50 (2001). 
196.  Gregory P. Lekovic, Genetic Diagnosis and Intellectual Property Rights: A 
Proposal to Amend “The Physician Immunity Statute”, 4 YALE J. HEALTH POL’Y, L. & 
ETHICS 275, 300 (2004) (“This is what Michael Heller and Rebecca Eisenberg have referred 
to as the ‘tragedy of the anticommons’ . . . in biomedical research.” (citing Michael Heller & 
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The aforementioned concerns suggest that “data sharing is the key 
to the future of genetic discoveries and bioinformatics, and [that] gene 
patents impede[] research aimed at identifying the role of genes in 
medical conditions.”197  From the beginning of the Human Genome 
project, many scientists and private companies have recognized the 
importance of keeping the genome freely available.  In 1994, the 
pharmaceutical company Merck funded a massive drive to generate 
gene sequences and place them into public databases, thereby making 
them difficult to patent.198  Shortly thereafter, a group of fifty prominent 
geneticists adopted the Bermuda principles in 1996 which advocated 
that all “human genome sequence information should be freely 
available in the public domain in order to encourage research and 
development and to maximize its benefit to society.”199 
In fact, in the case of genetic diagnostics, patent protection may 
“raise the cost of healthcare while inhibiting its effective delivery.”200  
The cost-benefit analysis indicates that enforcing the patents carries 
with it significant costs and minimal benefits.  “In other words, 
enforcing the patent would increase transaction costs and allow for the 
extraction of excess rents, the concerns raised by those critical of broad 
upstream patenting.”201 
C. A Lower Standard of Care 
Patents on genetic diagnostics also potentially threaten to lower the 
quality of medical care by presenting physicians with a Hobson’s choice 
between violating either patent laws or their ethical duties.  In 1995, 
controversy erupted over the case of Pallin v. Singer,202 which involved a 
method patent for performing cataract surgery that did not require 
stitches.  Pallin, the ophthalmologist who held the patent, sued another 
ophthalmologist for patent infringement for using his technique without 
obtaining a license.  The case sparked a great deal of controversy and 
was heavily criticized by the AMA as a violation of physicians’ ethical 
obligations to share their discoveries. 
 
Rebecca Eisenberg, Can Patents Deter Innovation?, 280 SCIENCE 698, 701 (1996)).   
197.  Ass’n of Molecular Pathology, 702 F. Supp. 2d at 208. 
198.  Id.   
199.  Id. (citing Sulston Decl. ¶ 33).   
200.  Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S. 124, 138 (2006) 
(Breyer, J., dissenting). 
201.  Harry First, Controlling the Intellectual Property Grab: Protect Innovation, Not 
Innovators, 38 RUTGERS L.J. 365, 385 (2007). 
202.  Pallin v. Singer, 1996 WL 274407 (D. Vt. Mar. 28, 1996). 
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Congress ultimately amended the Patent Act in 1996 in response to 
these concerns.  Under § 287(c), health care practitioners can be found 
liable for infringement, but cannot be subjected to monetary damages or 
injunctions for using patented medical or surgical techniques in medical 
practice.203  However, the amendment was limited to medical 
practitioners who infringe a patent in the course of medical activity and 
did not cover clinical laboratory testing.  35 U.S.C. § 287(c) is limited to 
the protection of “medical practitioners who infringe a patent in the 
course of medical activity.”204  It was not extended to cover “the practice 
of a patented use of a composition of matter in violation of such patent, 
or . . . the practice of a process in violation of a biotechnology patent,” 
or “the provision of pharmacy or clinical laboratory services (other than 
clinical laboratory services provided in a physician’s office).”205  Thus, 
clinicians are not exempt from liability for infringing biotechnology 
patents and can be held liable for “contributing to infringement by 
others” by providing physicians with information or guidelines related 
to performing patented processes.206 
Patents on genetic diagnostics also potentially threaten to lower the 
quality of medical care.  These patents 
[M]ay inhibit doctors from using their best medical judgment; 
they may force doctors to spend unnecessary time and energy to 
enter into license agreements; they may divert resources from 
the medical task of health care to the legal task of searching 
patent files for similar simple correlations; they may raise the 
cost of health care while inhibiting its effective delivery.”207 
In some instances, patients may be forced into the difficult position 
of having to make life-changing decisions without the ability to obtain a 
second opinion due to the existence of a gene patent.  This was 
 
203.  35 U.S.C. § 287(c) (2006).  This is sometimes referred to as the Frist-Ganske 
medical procedures exemption statute. 
204.  Id. 
205.  Id. 
206.  See H.R. 3967, 107th Cong. (2002) (In 2002, Rep. Lynn Rivers introduced the 
Genomic Research and Diagnostic Accessibility Act, which included a provision which would 
have allowed researchers and medical practitioners to use patented gene sequences for 
noncommercial research purposes and exempted clinicians performing genetic tests from 
patent infringement liability.  The bill did not become law.  
(http://www.govtrack.us/congress/bill.xpd?bill=h107-3967)).   
207.  Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S. 124, 138 (2006) 
(Breyer, J., dissenting). 
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evidenced by Myriad Genetics’ use of its gene patents, in which, in many 
cases, women facing potentially life-threatening decisions as to the 
proper course of care were prevented from obtaining a second set of test 
results. 
Genetic diagnostic patents also may place medical practitioners in 
the untenable position of having to choose between violating their 
ethical duties as physicians or violating patent laws.208  An accurate 
diagnosis is crucial in deciding on an effective treatment in the medical 
profession, where the Hippocratic Oath admonishes doctors to “First, 
do no harm.”  However, diagnostic gene patents can prevent doctors 
from providing their patients with an accurate diagnosis.  For example, 
Myriad Genetics did not permit researchers to inform patients involved 
in research of the results of their genetic testing, which often left 
physicians unable to meet their ethical obligations to provide test results 
to research subjects, upon request.209  The AMA has stated that the “use 
of patents . . . or other means to limit the availability of medical 
procedures places significant limitation on the dissemination of medical 
knowledge, and is therefore unethical.”210 
The decision in LabCorp highlights some of the absurdities of 
diagnostic patents.  In upholding the diagnostic patents, the Federal 
Circuit was forced to find the doctors guilty of direct patent 
infringement based on testimony that “it would be malpractice for a 
doctor to receive a total homocysteine assay without determining 
cobalamin/folate deficiency.”211  Because a competent doctor reviewing 
the results would correlate those results with the presence or absence of 
a vitamin deficiency, virtually every doctor who ordered and read the 
tests was a direct infringer.  Likewise, defendants were found guilty of 
inducing infringement based on publications in medical journals noting 
the diagnostic correlation.  The Federal Circuit held that “a reasonable 
jury could find intent to induce infringement because LabCorp’s articles 
stated that elevated total homocysteine correlates to cobalamin/folate 
 
208.  See, e.g., Metabolite Labs. Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 
1365 (Fed. Cir. 2004) (finding the fact that doctors who did not find a correlation would be 
liable of medical malpractice was circumstantial evidence that doctors violated patent).   
209.  Ass’n of Molecular Pathology v. U.S. Pat. & Trademark Office, 702 F. Supp. 2d 
181, 209 (S.D.N.Y. 2010). 
210.  American Medical Association, Op. 9.095, The use of Patents and Other Means to 
Limit Availability of Medical Procedures, (adopted June 1995), available at http://www.ama-
assn.org/ama/pub/physician-resources/medical-ethics/code-medical-ethics/opinion9095.shtml 
(last visited February 28, 2011).  
211.  Lab. Corp. of Am. Holdings, 370 F.3d at 1364. 
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deficiency.”212  Thus, all that was necessary for the doctor’s application 
of the correlation was knowledge of it. 
V. CONCLUSION 
The diagnostic gene patents at issue in Molecular Pathology, and 
other diagnostic patents which attempt to usurp all practical 
applications of an abstract idea, constitute non-patentable subject 
matter.  Diagnostic patents that give exclusive private ownership, “not 
of a new drug, or of a new diagnostic test, or even of a new method of 
diagnosing a particular disease - but rather of a scientific observation”213 
are not deserving of patent protection. 
 
 
212.  Id. at 1365.  
213.  Brief for American Medical Ass’n, et al. as Amici Curiae Supporting Defendant-
Appellees, Ass’n for Molecular Pathology v. U.S. Pat. & Trademark Office, 2009 WL 1307167 
(Apr. 6, 2009). 
